Abstracted Scientific Content

Published in:
Volume 3 / Year 2014 / Issue 2

Weighing up the cost of switching to biosimilars

Page: 100

It is far from clear whether off-patent biological medicines can offer the same cost savings as those offered by off-patent non-biological (chemically derived) medicines, write a group of Brussels-based health… Read More »

Go Back Print